News|Articles|September 3, 2026

Latest Vaccine and Immunization Efficacy, Safety for RSV, Influenza, and COVID-19

The Vaccine Integrity Project, in collaboration with the American Medical Association, conducted a vaccine and immunization effectiveness and safety review for RSV, Influenza, and COVID-19 for the 2026-2027 season. JAMA published the review, and here is an overview of the data going into this year's seasonal respiratory virus season.

The respiratory virus season is upon the northern hemisphere and the Vaccine Integrity Project, in collaboration with the American Medical Association (AMA), conducted a vaccine and immunization effectiveness and safety review for RSV, Influenza, and COVID-19 for the 2026-2027 season.

Related to this article

October 15th, 2026

VaxImpactMap Projects State-Level Burden of Declining Childhood Vaccination

Projected disease burden from declining childhood vaccine coverage shows increases in vaccine-preventable diseases. Benjamin Lopman, PhD, provides insights on how VaxImpactMap works and the potential long-term disease consequences of decreased immunization rates.

October 12th, 2026

NFID Survey Finds Respiratory Vaccine Gap Driven by Lack of Clarity, Not Hesitancy

The National Foundation for Infectious Diseases (NFID) recently held its respiratory season kick-off, which included the release of its annual respiratory disease survey. This year, the survey revealed the gap between vaccine support and uptake. Robert Hopkins Jr, MD, medical director of NFID delves deeper into the findings of the survey and the vaccine uptake challenges associated with certain immunizations.

October 3rd, 2026

Clesrovimab Given in 1st and 2nd RSV Seasons for At-Risk Infants

A study finding clesrovimab comparable to palivizumab in protecting at-risk infants in their first RSV season was extended to demonstrate clesrovimab effective and well-tolerated when administered in their second season.

October 13th, 2026

Pennsylvania Coroner Reports Sixth Measles-Related Death

A 39-year-old unvaccinated Franklin County woman has died after a recent measles diagnosis. Nationally, numbers continue to increase and the US has passed 4,000 cases.

October 9th, 2026

Measles Update: October 9, 2026

The latest CDC numbers show a 5.0% increase of measles cases from week-to-week. The US total reached 4080 confirmed cases, 78% above all of 2025.

October 7th, 2026

FAQ: What You Need to Know About Measles in 2026

With US measles cases nearing 3,900 this year and Pennsylvania reporting its fifth measles-related death, here is a review of how the virus spreads, how it is prevented and managed, and what severe disease looks like.

October 7th, 2026

VAX-31 Meets Primary Endpoints in Phase 3 Pneumococcal Vaccine Study

Vaxcyte's 31-valent pneumococcal conjugate vaccine candidate met every prespecified primary immunogenicity and safety endpoint against PCV20 and PCV21 in the OPUS-1 trial of 4,047 US adults.

September 29th, 2026

VYD2311 Shows Superior Tolerability to mRNA COVID-19 Vaccine in Phase 3 Study

In the phase 3 LIBERTY study, the investigational monoclonal antibody, VYD2311, had significantly fewer adverse events than an mRNA COVID-19 vaccine, and it did not blunt vaccine-induced neutralizing titers when the two were given together.